Pasithea Therapeutics Dividends
| KTTA Stock | USD 0.69 0.02 2.82% |
As of February 18, 2026, Dividends Paid is expected to decline to about 287.7 M. In addition to that, Dividend Paid And Capex Coverage Ratio is expected to decline to -472.62. Pasithea Therapeutics' past performance could be the main factor of why investors trade Pasithea Therapeutics Corp stock today. Investors should clearly understand every aspect of the Pasithea Therapeutics dividend schedule, including its future sustainability, and how it might impact an overall investment strategy. This tool is helpful to digest Pasithea Therapeutics' dividend schedule and payout information. Pasithea Therapeutics Corp dividends can also provide a clue to the current valuation of Pasithea Therapeutics.
| Last Reported | Projected for Next Year | ||
| Dividends Paid | 323.7 M | 287.7 M | |
| Dividend Paid And Capex Coverage Ratio | (450.11) | (472.62) |
Investing in stocks that pay dividends is one of many strategies that are good for long-term investments. Ex-dividend dates are significant because investors in Pasithea Therapeutics must own a stock before its ex-dividend date to receive its next dividend.
Pasithea Therapeutics Dividends Paid Over Time
Today, most investors in Pasithea Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Pasithea Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's dividends paid growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Pasithea Therapeutics dividends paid as a starting point in their analysis.
The total amount of dividends that a company has paid out to its shareholders over a specific period. Dividends Paid |
| Timeline |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pasithea Therapeutics. Expected growth trajectory for Pasithea significantly influences the price investors are willing to assign. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Pasithea Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (4.43) | Revenue Per Share | Quarterly Revenue Growth 14.981 | Return On Assets | Return On Equity |
The market value of Pasithea Therapeutics is measured differently than its book value, which is the value of Pasithea that is recorded on the company's balance sheet. Investors also form their own opinion of Pasithea Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Pasithea Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pasithea Therapeutics' market value can be influenced by many factors that don't directly affect Pasithea Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Pasithea Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Pasithea Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Pasithea Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.